<DOC>
	<DOCNO>NCT02675218</DOCNO>
	<brief_summary>Rheumatoid Arthritis patient management repose primarily use disease-modifying antirheumatic drug ( DMARDs ) . Among DMARDs available 2015 , researcher demonstrate ability reduce synovitis , biomarkers inflammation , bone destruction . Given demonstration correlation joint inflammation structural progression joint level well opportunity bone remodel resolution joint inflammation , researcher expect observe improvement bone micro-architecture parameter specifically rheumatoid arthritis patient without remain joint inflammation 3 month follow abatacept treatment initiation .</brief_summary>
	<brief_title>Bone MicroArchitecture Abatacept ( BMA2 )</brief_title>
	<detailed_description>Rheumatoid Arthritis patient management repose primarily use disease-modifying anti-rheumatic drug . In patient respond insufficiently Methotrexate , and/or disease-modifying anti-rheumatic drug ( DMARD ) strategy , without glucocorticoid , biological DMARD ( TNF inhibitor , abatacept tocilizumab , , certain circumstance , rituximab ) commence Methotrexate . Among DMARD available 2015 , abatacept demonstrated ability reduce synovitis , biomarkers inflammation , bone destruction . Monitoring rheumatoid arthritis patient start abatacept US exams observe strong reduction power Doppler ultra-sonography 3 month two third patient . Given demonstration correlation joint inflammation structural progression joint level well opportunity bone remodel resolution joint inflammation , researcher expect observe improvement bone micro-architecture parameter specifically rheumatoid arthritis patient without remain joint inflammation 3 month follow abatacept initiation .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Signed date informed consent form , Age ≥ 18 year , Rheumatoid arthritis diagnosis accord ACR/EULAR 2010 criterion Abatacept therapy subcutaneous require accord EULAR recommendation Patients affiliate health insurance Other arthritis rheumatoid arthritis , Contraindication abatacept , Concomitant treatment zoledronic acid ( Aclasta® ) denosumab ( Prolia® ) , Injection intravenously intraarticular 2nd 3rd metacarpophalangeal joint dominant hand 3 month prior inclusion , Prior plan joint surgery 2nd 3rd metacarpophalangeal joint dominant hand one year study , No recent use high density contrast material , Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>